Unlock instant, AI-driven research and patent intelligence for your innovation.

6-deoxy alpha-amino acid derivative cyclodextrin, preparation and application thereof

A derivative and amino acid technology, which is applied in the field of 6-deoxy α-amino acid derivative cyclodextrin and its preparation and application, can solve the problems of non-inclusion and poor antagonism effect, and achieve high yield, stable preparation process, and improved The effect of medicine

Active Publication Date: 2012-12-26
HANGZHOU ADAMERCK PHARMLABS INC
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0012] The main disadvantage of Sugammadex is that it can only antagonize the muscle relaxation antagonism caused by rocuronium bromide and vecuronium bromide. Ammonium, etc. have the disadvantage of poor reversal or antagonistic effect
[0020] The advantage is that it has better selectivity, but the structure of the compound does not include the substitution of the amino acid at the α-position and its derivatives

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • 6-deoxy alpha-amino acid derivative cyclodextrin, preparation and application thereof
  • 6-deoxy alpha-amino acid derivative cyclodextrin, preparation and application thereof
  • 6-deoxy alpha-amino acid derivative cyclodextrin, preparation and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0049]

[0050]A solution of L-cysteine ​​(1.5g, 8.54mmol) in water (5ml) was added to the reaction flask, and mixed with 1M sodium bicarbonate (25.62ml) and benzyl chloroformate 1.32ml (9.41mmol). The reaction was stirred at 0°C for 4 hours, then cooled to room temperature and extracted with ether to remove excess benzyl chloroformate. The aqueous phase was acidified to PH=3 by adding hydrochloric acid, extracted with ethyl acetate, dried, and the solvent was removed to obtain the product (CD-1) with a yield of 93%.

[0051]

[0052] Weigh dry CD-16g (0.024mol), measure dehydrated 60ml DMF, add to a dry three-necked flask, stir until fully dissolved and colorless solution. The temperature of the reaction solution was lowered to -20°C under a constant temperature cooling bath, and 2.35 g (0.059 mol) of sodium hydride (60%) was slowly added in batches, protected by argon, mechanically stirred, and the temperature was controlled below -5°C. Continue to stir until no bubbl...

Embodiment 27

[0139] Dutch guinea pigs were injected with atropine 30 minutes before the operation, and after intraperitoneal anesthesia with pentobarbital sodium, the guinea pigs were fixed on the mouse board, connected to a small animal ventilator after endotracheal intubation, and the stimulation electrodes of the TOF-Watch SX muscle relaxation monitor were respectively It was connected under the skin of the left femur and posterior tibia of the guinea pig, and the left tibia was fixed on a small platform with self-made tools, and the left hind paw could move freely. The sensor was fixed on the palm of the left hind paw of the guinea pig, and the skin temperature probe was fixed on the palm of the left forepaw. Adjust 4 serial stimulations (TOF, frequency 2 Hz, wave width 0.2 ms, interval between strings 15 s), TOF stimulation voltage 5 mA; adjust the sensitivity so that T1 is stable for more than 5 min, and inject rocuronium bromide intravenously , 50mg / 5ml) 0.16mg / kg (2 times ED90 dose...

Embodiment 28

[0148] Male mice were given the compound of the present invention by tail vein injection, and the toxic reaction was observed. See Table 2 for the results.

[0149] Table 2

[0150] group Dosing concentration dose Dosage result description CD-8 200mg / ml 4000mg / kg 0.4ml normal CD-10 200mg / ml 4000mg / kg 0.8ml normal CD-19 200mg / ml 4000mg / kg 0.6ml normal CD-23 200mg / ml 4000mg / kg 0.7ml normal CD-28 200mg / ml 4000mg / kg 0.3ml normal CD-30 200mg / ml 4000mg / kg 0.5ml normal CD-32 200mg / ml 4000mg / kg 0.7ml normal

[0151] [0150] According to literature reports, the maximum immortal dose of CN1402737's marketed product Bridion mice is 2000mg / kg, given the compounds of the present invention CD-8, CD-10, CD-19, CD-23, CD-28, CD-30 or CD-32 When the dose was 4000mg / kg, the mice were still normal, indicating that the safe dose of the compound of the present invention was doub...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

6-deoxy-6-thioether-amino acid cyclodextrin derivative is obtained by condensing an amino acid derivative with halogenated cyclodextrin in presence of alkali. The 6-deoxy-6-thioether-amino acid cyclodextrin derivative includes 6-deoxysulfinyl-6-thioether-amino acid cyclodextrin derivative and 6-deoxysulfonyl-6-thioether-amino acid cyclodextrin derivative. Compounds provided are for reversing neuromuscular relaxation in patients and animals induced by muscular relaxants. The compounds are able to rapidly reverse and antagonize muscular relaxation induced by muscular relaxants and can be administrated in preparing a drug having an antagonist effect on muscular relaxation. The compounds have low production cost and are able to reverse and antagonize a wide rage of muscular relaxations, thus effectively broaden scope of clinical use. More importantly, the compounds have a safe dose at least doubled compared to prior arts. The compounds have a general formula (I).

Description

technical field [0001] The invention belongs to the field of chemical industry and pharmacy, and relates to 6-deoxy α-amino acid derivative cyclodextrin and its preparation method, mainly related to 6-deoxysulfide α-amino acid derivative cyclodextrin, 6-deoxysulfoxide α-amino acid derivative Cyclodextrin, 6-deoxysulfone-based α-amino acid derivative cyclodextrin and its preparation method, as well as the use in the preparation of muscle relaxation antagonistic drugs, said compound can quickly reverse the muscle relaxation caused by muscle relaxants , and has high safety, and also has the characteristics of easy availability of reaction raw materials and low production cost. technical background [0002] In 1986, Tubashi.I. reported the synthesis of o-carboxyphenylthiocyclodextrin in J.A.C.S.; in 1995, Guillo.F. reported the synthesis of carboxymethylthiocyclodextrin; in 1996, Baer.H.H. and Santoyo-Gonzalez. F. Preparation of 2,3-dihydroxypropylthiocyclodextrin. Its structu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C08B37/16A61K31/724A61P21/00
CPCA61K47/48A61K31/724C08B37/0012A61K9/00A61K47/40A61P21/00A61P21/02
Inventor 漆又毛
Owner HANGZHOU ADAMERCK PHARMLABS INC